• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effects of low-dose amiodarone and Betaloc on the treatment of hypertrophic cardiomyopathy complicated with malignant ventricular arrhythmias.小剂量胺碘酮与倍他乐克治疗肥厚型心肌病合并恶性室性心律失常的效果比较。
Pak J Med Sci. 2014 Mar;30(2):291-4.
2
Amiodarone reduces QT dispersion in patients with hypertrophic cardiomyopathy.胺碘酮可降低肥厚型心肌病患者的QT离散度。
Int J Cardiol. 1992 Sep;36(3):345-9. doi: 10.1016/0167-5273(92)90305-m.
3
Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol.胺碘酮长期治疗对犬心室复极跨壁异质性的影响:与急性索他洛尔的相互作用
Cardiovasc Res. 1999 Nov;44(2):303-14. doi: 10.1016/s0008-6363(99)00232-1.
4
Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome.胺碘酮对危及生命的室性心律失常患者QT离散度及临床结局的影响。
Int J Cardiol. 1997 Aug 8;60(3):289-94. doi: 10.1016/s0167-5273(97)00073-9.
5
Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.非持续性室性心动过速作为特发性扩张型心肌病患者猝死的预测指标。胺碘酮治疗的作用。
G Ital Cardiol. 1999 May;29(5):514-23.
6
QT interval dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias?QT间期离散度:持续性室性心律失常患者心律失常易感性的无创标志物?
Br Heart J. 1994 Jun;71(6):511-4. doi: 10.1136/hrt.71.6.511.
7
[Effects of combined amiodarone and antiarrhythmic peptide use on the cardiac gap junctions and incidence of induced ventricular arrhythmias in healed myocardial infarction rabbit models].[胺碘酮与抗心律失常肽联合应用对心肌梗死愈合兔模型心脏缝隙连接及诱发室性心律失常发生率的影响]
Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Dec;38(12):1102-7.
8
Ambulatory assessment of the QT interval in patients with hypertrophic cardiomyopathy: risk stratification and effect of low dose amiodarone.肥厚型心肌病患者QT间期的动态评估:风险分层及低剂量胺碘酮的作用
Pacing Clin Electrophysiol. 1994 Nov;17(11 Pt 2):2222-7. doi: 10.1111/j.1540-8159.1994.tb03830.x.
9
QT dispersion predicts ventricular arrhythmia in pediatric cardiomyopathy patients referred for heart transplantation.QT离散度可预测因心脏移植而转诊的小儿心肌病患者发生室性心律失常。
J Heart Lung Transplant. 1999 Aug;18(8):781-5. doi: 10.1016/s1053-2498(99)00010-8.
10
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.胺碘酮改善肥厚型心肌病合并室性心动过速患者的生存率。
Br Heart J. 1985 Apr;53(4):412-6. doi: 10.1136/hrt.53.4.412.

引用本文的文献

1
Reduced-dose Antiarrhythmic Drugs: Valuable or Valueless?低剂量抗心律失常药物:有价值还是无价值?
J Innov Card Rhythm Manag. 2020 Apr 15;11(4):4063-4067. doi: 10.19102/icrm.2020.110404. eCollection 2020 Apr.
2
Low-dose Amiodarone Is Safe: A Systematic Review and Meta-analysis.低剂量胺碘酮是安全的:一项系统评价和荟萃分析。
J Innov Card Rhythm Manag. 2020 Apr 15;11(4):4054-4061. doi: 10.19102/icrm.2020.110403. eCollection 2020 Apr.
3
Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death.胺碘酮与其他预防心源性猝死的药物干预措施的比较
Cochrane Database Syst Rev. 2015 Dec 8;2015(12):CD008093. doi: 10.1002/14651858.CD008093.pub2.

本文引用的文献

1
Why and how to support screening strategies to prevent sudden death in athletes.为何及如何支持筛查策略以预防运动员猝死。
Cell Tissue Res. 2012 May;348(2):315-8. doi: 10.1007/s00441-012-1398-4. Epub 2012 Mar 29.
2
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.2011年美国心脏病学会基金会/美国心脏协会肥厚型心肌病诊断和治疗指南:美国心脏病学会基金会/美国心脏协会实践指南工作组报告。与美国胸外科协会、美国超声心动图学会、美国核心脏病学会、美国心力衰竭学会、心律学会、心血管造影和介入学会以及胸外科医师学会合作制定。
J Am Coll Cardiol. 2011 Dec 13;58(25):e212-60. doi: 10.1016/j.jacc.2011.06.011. Epub 2011 Nov 8.
3
Longitudinal left ventricular strain in hypertrophic cardiomyopathy: correlation with nonsustained ventricular tachycardia.肥厚型心肌病患者的纵向左心室应变:与非持续性室性心动过速的相关性
Echocardiography. 2011 Aug;28(7):709-14. doi: 10.1111/j.1540-8175.2011.01427.x. Epub 2011 May 12.
4
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.心肌纤维化作为肥厚型心肌病的早期表现。
N Engl J Med. 2010 Aug 5;363(6):552-63. doi: 10.1056/NEJMoa1002659.
5
Sarcomere gene mutations in hypertrophy and heart failure.肌节基因突变与心肌肥厚和心力衰竭。
J Cardiovasc Transl Res. 2010 Aug;3(4):297-303. doi: 10.1007/s12265-010-9188-4. Epub 2010 May 25.
6
Relationship of functional mitral regurgitation to new-onset atrial fibrillation in acute myocardial infarction.急性心肌梗死后功能性二尖瓣反流与新发心房颤动的关系。
Heart. 2010 May;96(9):683-8. doi: 10.1136/hrt.2009.183822.
7
Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations.与三肌节蛋白基因突变相关的肥厚型心肌病的临床特征和结局。
J Am Coll Cardiol. 2010 Apr 6;55(14):1444-53. doi: 10.1016/j.jacc.2009.11.062.
8
Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution.酒精室间隔消融术治疗梗阻性肥厚型心肌病患者的长期疗效:需要谨慎。
Circ Heart Fail. 2010 May;3(3):362-9. doi: 10.1161/CIRCHEARTFAILURE.109.862359. Epub 2010 Mar 23.
9
Atorvastatin might improve ventricular electrostability and decelerate the deterioration of renal function in patients with heart failure and diabetes mellitus.阿托伐他汀可能改善心力衰竭合并糖尿病患者的心室电稳定性并延缓肾功能恶化。
J Cardiol. 2009 Jun;53(3):341-8. doi: 10.1016/j.jjcc.2008.12.002. Epub 2009 Feb 6.
10
Cardiac fibroblasts: at the heart of myocardial remodeling.心脏成纤维细胞:心肌重塑的核心
Pharmacol Ther. 2009 Aug;123(2):255-78. doi: 10.1016/j.pharmthera.2009.05.002. Epub 2009 May 19.

小剂量胺碘酮与倍他乐克治疗肥厚型心肌病合并恶性室性心律失常的效果比较。

Effects of low-dose amiodarone and Betaloc on the treatment of hypertrophic cardiomyopathy complicated with malignant ventricular arrhythmias.

机构信息

Yu Gao, Second Department of Cardiology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P. R. China.

Peisheng Zhang, Second Department of Cardiology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P. R. China.

出版信息

Pak J Med Sci. 2014 Mar;30(2):291-4.

PMID:24772129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3998996/
Abstract

OBJECTIVE

To study the therapeutic effects of low-dose amiodarone and Betaloc on hypertrophic cardiomyopathy complicated by malignant ventricular arrhythmias.

METHODS

Eighty-two such patients were selected and divided into a treatment group and a control group by the random number method (n=41), which were administered with low-dose amiodarone plus Betaloc and individual Betaloc respectively.

RESULTS

The treatment group had a significantly higher overall effective rate (85.4%) than the control group (65.9%) did. Based on the New York Heart Association's classification of cardiovascular disease, the treatment group mainly comprised Class III and IV patients before treatment, which were significantly relieved after treatment (P<0.05). The heart rate was evidently decreased from (119.99±18.91) bpm to (80.98±12.34) bpm, and the incidences of premature ventricular contraction and tachycardia were significantly reduced (P<0.05). The longest QT intervals after and before treatment were (421±32) ms and (411±35) ms respectively. The shortest QT interval after treatment [(350±36) ms] was significantly longer than that before [(307±31) ms]. The QT dispersion before treatment [(96±29) ms] was significantly higher that after [(64±17) ms] (P<0.05). Six out of eighty two patients in the treatment group succumbed to adverse reactions (14.63%).

CONCLUSION

Hypertrophic cardiomyopathy complicated with malignant ventricular arrhythmias can be well treated with low-dose amiodarone and Betaloc, with mitigated symptoms, improved prognosis and few adverse reactions.

摘要

目的

研究小剂量胺碘酮和倍他乐克治疗肥厚型心肌病并发恶性室性心律失常的疗效。

方法

选择 82 例肥厚型心肌病并发恶性室性心律失常患者,采用随机数字表法分为治疗组和对照组(n=41),分别采用小剂量胺碘酮联合倍他乐克、倍他乐克个体化治疗。

结果

治疗组总有效率(85.4%)明显高于对照组(65.9%)。根据纽约心脏病协会(NYHA)心血管病分级,治疗组治疗前主要为Ⅲ、Ⅳ级患者,治疗后明显缓解(P<0.05)。心率从(119.99±18.91)次/min 明显下降至(80.98±12.34)次/min,室性早搏和心动过速的发生率明显降低(P<0.05)。治疗前后最长 QT 间期分别为(421±32)ms 和(411±35)ms,治疗后最短 QT 间期(350±36)ms 明显长于治疗前(307±31)ms,治疗前 QT 离散度(96±29)ms 明显高于治疗后(64±17)ms(P<0.05)。治疗组 82 例患者中有 6 例死亡(14.63%)。

结论

小剂量胺碘酮和倍他乐克治疗肥厚型心肌病并发恶性室性心律失常,可有效缓解症状,改善预后,不良反应少。